Drug_Name,STUDYID,YEAR,Country,Dataset,Patient_Count,Median_Age,Female_Percentage,Male_Percentage,Median_BMI,Smoking_History_Yes_Percentage,Total_ADL_Independence_Percentage,LHRH_Use_Percentage,Tumor_Stage_T1_Percentage,Tumor_Stage_T2_Percentage,Tumor_Stage_T3_Percentage,Tumor_Stage_T4_Percentage,Nodal_Stage_N0_Percentage,Nodal_Stage_N1_Percentage,Nodal_Stage_N2_Percentage,Nodal_Stage_N3_Percentage,Stage_I_Percentage,Stage_II_Percentage,Stage_III_Percentage,Diabetes_Mellitus_Percentage,Congestive_Heart_Failure_Percentage,Stroke_Percentage,Atrial_Fibrillation_Percentage,Myocardial_Infarction_Percentage,Neoadjuvant_Chemotherapy_Received_Percentage,Adjuvant_Chemotherapy_Received_Percentage,Postoperative_RT_Received_Percentage,Common_Neoadjuvant_Regimen_1,Common_Neoadjuvant_Regimen_2,Common_Adjuvant_Regimen_1,Common_Adjuvant_Regimen_2,Tamoxifen_Percentage,Letrozole_Percentage,Anastrozole_Percentage,Antidiarrheal_Agent_Probiotics_Percentage,Antiemetic_Agent_Percentage,Painkiller_Antipyretic_Percentage,Beds_Less_Than_200_Percentage,Beds_200_To_499_Percentage,Beds_Greater_Or_Equal_To_500_Percentage,Designated_Cancer_Hospital_Percentage,Months_Between_Surgery_And_Index_Date
Ribociclib,RiboStudy001,2022,USA,MDV,350,62,98,2,27.5,15,85,5,10,45,30,15,60,25,10,5,15,50,35,12,3,2,5,4,8,45,30,AC,TC,CMF,Taxol,20,35,40,25,50,60,10,55,35,65,2
Ribociclib,RiboStudy002,2023,Canada,Claim Database,420,68,97,3,28.1,18,78,7,12,40,33,15,55,30,10,5,18,45,37,15,4,3,7,5,10,50,35,AC-T,FEC,AC,Docetaxel,25,30,45,30,55,65,15,50,35,70,3
Ribociclib,RiboStudy003,2023,UK,MDV,280,59,99,1,26.9,12,90,3,8,48,28,16,65,20,8,7,12,55,33,10,2,1,4,3,6,40,25,EC,CMF,FEC-T,AC-T,15,40,35,20,45,55,8,60,32,75,1
Ribociclib,RiboStudy004,2024,Germany,Claim Database,480,71,96,4,29.3,20,75,9,14,38,35,13,50,35,9,6,20,40,40,18,5,4,8,6,12,55,40,Taxane-based,Anthracycline-based,AI,Cyclophosphamide,30,25,45,35,60,70,20,45,35,60,4
